title: In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).
abstract: We examined the effect of immune stimulation by a human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) compared to a non-HIV vaccine (influenza) on HIV-1-specific immune responses in HIV-1-seropositive subjects. HIV-1 p24 antigen-stimulated lymphocyte proliferation was not augmented after immunization with the influenza vaccine. In contrast, subjects increased their lymphocyte proliferative responses to p24 antigen after one immunization with HIV-1 immunogen (Remune) (gp120-depleted inactivated HIV-1 in incomplete Freund's adjuvant). Furthermore, p24 antigen-stimulated beta-chemokine production (RANTES, MIP-1alpha, MIP-1beta) was also augmented after immunization with the HIV-1 immunogen but not influenza vaccine. Taken together, these results suggest that in this cohort, HIV-specific immune responses to p24 antigen can be augmented after immunization with an HIV-1 immunogen. The ability to upregulate immune responses to the more conserved core proteins may have important implications in the development of immunotherapeutic interventions for HIV-1 infection.
authors.affiliation: The Immune Response Corporation, Carlsbad, California 92008, USA. shotdoc@imnr.com
authors.forename: R B
authors.initials: RB
authors.lastname: Moss
authors.forename: M R
authors.initials: MR
authors.lastname: Wallace
authors.forename: P
authors.initials: P
authors.lastname: Lanza
authors.forename: W
authors.initials: W
authors.lastname: Giermakowska
authors.forename: F C
authors.initials: FC
authors.lastname: Jensen
authors.forename: G
authors.initials: G
authors.lastname: Theofan
authors.forename: C
authors.initials: C
authors.lastname: Chamberlin
authors.forename: S P
authors.initials: SP
authors.lastname: Richieri
authors.forename: D J
authors.initials: DJ
authors.lastname: Carlo
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D018791:CD4 Lymphocyte Count; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018946:Chemokine CCL5 / Q000096:biosynthesis; D018925:Chemokines / Q000096:biosynthesis*; D016655:HIV Core Protein p24 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology; D008213:Lymphocyte Activation; D019402:Macrophage Inflammatory Proteins / Q000096:biosynthesis; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018946:Chemokine CCL5; D018925:Chemokines; D016655:HIV Core Protein p24; D007252:Influenza Vaccines; D019402:Macrophage Inflammatory Proteins; D015164:Vaccines, Inactivated; C105086:remune